
SRX3177
CAS No. 2241237-51-2
SRX3177( —— )
Catalog No. M36306 CAS No. 2241237-51-2
SRX3177 is a novel and potent inhibitor of BRD4, PI3K and CDK.SRX3177 has potential anticancer activity.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 225 | Get Quote |
![]() ![]() |
5MG | 353 | Get Quote |
![]() ![]() |
10MG | 567 | Get Quote |
![]() ![]() |
25MG | 860 | Get Quote |
![]() ![]() |
50MG | 1159 | Get Quote |
![]() ![]() |
100MG | 1521 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameSRX3177
-
NoteResearch use only, not for human use.
-
Brief DescriptionSRX3177 is a novel and potent inhibitor of BRD4, PI3K and CDK.SRX3177 has potential anticancer activity.
-
DescriptionSRX3177 is a triple inhibitor of CDK4/6, PI3K, and BRD4, with IC50s of 33 nM (BRD4 BD1), 89 nM (BRD4 BD2), 79 nM (PI3Kα), 83 nM (PI3Kδ), 3.18 μM (PI3Kγ), <2.5 nM (CDK4), 3.3 nM (CDK6), respectively. SRX3177 exerts broad cytotoxic activity against cancer cells, but acts friendly with normal epithelial cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain | PI3K | CDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2241237-51-2
-
Formula Weight584.69
-
Molecular FormulaC31H32N6O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (42.76 mM; Ultrasonic )
-
SMILESC(N(C)C)(=O)C=1N(C=2C(C1)=CN=C(NC3=CC=C(C=C3)C=4C5=C(SC4)C(=O)C=C(O5)N6CCOCC6)N2)C7CCCC7
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Burgoyne AM, et al. A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity. Cell Discov. 2020 Jul 28;6(1):49.?
molnova catalog



related products
-
SRX3177
SRX3177 is a novel and potent inhibitor of BRD4, PI3K and CDK.SRX3177 has potential anticancer activity.
-
Butyrolactone 3
Butyrolactone 3 (MB-3) is a histone acetyltransferase Gcn5 inhibitor with a weak affinity for CBP.Butyrolactone 3 has antimicrobial activity and has been used in cancer, metabolic and neurological disorders.
-
SMARCA-BD ligand 1 f...
SMARCA-BD ligand 1 for Protac is a compound that binds to SMARCA2, the BAF ATPase subunit, utilizing Protac technology to degrade SMARCA2.